中度至重度性结肠炎的最佳生物疗法是什么:系统性审查和网络元分析
Longbin Huang1, Chen Kong1, Ningning Yue1
1Department of Gastroenterology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China.
Frontiers in pharmacology
|July 28, 2025
概括
这项研究比较了中度至重度性结肠炎 (UC) 的生物药物. 因弗利西马布和维多利祖马布在诱导和维持方面表现最好,大多数生物药物是安全的,耐受性良好.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物疗法已经成为管理中度至重度性结肠炎 (UC) 的关键.
- 越来越多的生物制剂需要进行比较分析来选择最佳的治疗方法.
- 了解这些药物的相对疗效和安全性对于临床决策至关重要.
研究的目的:
- 进行更新的网络元分析,比较生物制剂在中度至重度UC的疗效和安全性.
- 通过先前的生物暴露来分层评估结果 (天真与暴露).
- 根据临床缓解,反应,内镜改善和安全性来对生物药物进行排名.
主要方法:
- 进行了系统的文献搜索,截至2024年5月18日.
- 包括23项试验,包括10,839名患者,评估临床缓解,反应,内镜改善和安全.
- 贝叶斯网络元分析被采用,利用相对比率 (RR),95%置信区间 (CI) 和表面下累积排名概率 (SUCRA) 进行排名.
主要成果:
- 对于诱导,因弗利西马布5mg/kg在临床缓解和内镜改善方面排名最高.
- 乌斯特基努马布6mg/kg在临床反应方面优越,特别是在生物暴露患者中.
- 维多利祖马布在维持疗法中表现出领先的疗效,用于缓解和内镜改善,而因弗利西马布在反应方面表现出色.
- 大多数活性生物制剂之间没有发现显著的安全差异,尽管视利祖马布和戈利穆马布显示出不同的安全概况.
结论:
- 在UC中,infliximab和vidolizumab被确定为高效的生物药物,用于UC的诱导和维持.
- 乌斯特基努马布和米里基祖马布表现出良好的安全性.
- 治疗选择应考虑患者的生物病史和特定的疗效结果.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
422
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
422
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235


